This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by WEINER, M. Articles by KATZKA, I. Search for Related Content PubMed PubMed Citation Articles by WEINER, M. Articles by KATZKA, I.

(Circulation. 1956;13:400.)
© 1956 American Heart Association, Inc.

---

An Evaluation of a New Anticoagulant, Acenocoumarin (Sintrom)

MURRAY WEINER M.D.¹; MARIANO JIMINEZ M.D.¹; IRWIN KATZKA M.D.¹

¹ From the Research Service, Third New York University Medical Division, Goldwater Memorial Hospital, and the Department of Medicine Long Island Jewish Hospital, New York, N. Y.

A new coumarin anticoagulant, acenocoumarin (Sintrom) is compared with other hypoprothrombinemic agents in the same human subjects. Comparing doses which result in the same peak prothrombin time, both speed of onset and duration of effect are found to be a function of the rate of biotransformation. Rapid biotransformation results in fast onset and short duration of action and vice versa. Sintrom is intermediate between the slow, long-acting compounds (Dicumarol, Warfarin, Coumopyrin) and the fast, short-acting Tromexan. One 16 to 32 mg. dose of Sintrom rapidly results in a desirable hypoprothrombinemia which is maintained by a single daily dose of 2 to 10 mg.

This article has been cited by other articles:

				F. ALEXANDER, J. L. KOPPEL, P. M. ARSCOTT, and J. H. OLWIN Clinical Experience with the Anticoagulant Acenocoumarin (Sintrom) Arch Intern Med, October 1, 1957; 100(4): 558 - 564. [Abstract] [PDF]